|
Atrial Fibrillation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.
|
30061737 |
2018 |
|
Paroxysmal atrial fibrillation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.
|
30061737 |
2018 |
|
Persistent atrial fibrillation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.
|
30061737 |
2018 |
|
familial atrial fibrillation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.
|
30061737 |
2018 |
|
Adrenal Gland Diseases
|
0.300 |
Therapeutic
|
group |
CTD_human |
The involvement of hypophyseal-gonadal and hypophyseal-adrenal axes in arsenic-mediated ovarian and uterine toxicity: modulation by hCG.
|
20146381 |
2010 |
|
Ovarian Diseases
|
0.300 |
Therapeutic
|
group |
CTD_human |
The involvement of hypophyseal-gonadal and hypophyseal-adrenal axes in arsenic-mediated ovarian and uterine toxicity: modulation by hCG.
|
20146381 |
2010 |
|
Uterine Diseases
|
0.300 |
Therapeutic
|
group |
CTD_human |
The involvement of hypophyseal-gonadal and hypophyseal-adrenal axes in arsenic-mediated ovarian and uterine toxicity: modulation by hCG.
|
20146381 |
2010 |
|
Endometrial Diseases
|
0.300 |
Therapeutic
|
group |
CTD_human |
The involvement of hypophyseal-gonadal and hypophyseal-adrenal axes in arsenic-mediated ovarian and uterine toxicity: modulation by hCG.
|
20146381 |
2010 |
|
Oligospermia
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Effects of chronic exposure to sodium arsenite on hypothalamo-pituitary-testicular activities in adult rats: possible an estrogenic mode of action.
|
16483355 |
2006 |
|
Hemiplegia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.
|
10566621 |
1999 |
|
Monoplegia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.
|
10566621 |
1999 |
|
Hemiplegia, Flaccid
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.
|
10566621 |
1999 |
|
Hemiplegia, Spastic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.
|
10566621 |
1999 |
|
Disease Exacerbation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.
|
10566621 |
1999 |
|
Hemiplegia, Crossed
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.
|
10566621 |
1999 |
|
Hemiplegia, Infantile
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.
|
10566621 |
1999 |
|
Hemiplegia, Transient
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.
|
10566621 |
1999 |
|
Hemiplegia, Post-Ictal
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.
|
10566621 |
1999 |
|
Thyroid cancer, follicular
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.
|
10566621 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Circulating tumor markers (β-subunit of human chorionic gonadotropin (β-HCG), alpha-Fetoprotein (AFP), and Lactate Dehydrogenase (LDH)) are frequently used for monitoring disease recurrence in TGCT patients, though they lack diagnostic sensitivity and specificity.
|
30321995 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Of these 19 patients, 17 did not have elevated CSF HCG-β levels or express HCG-β in the tumor tissue.
|
28819802 |
2018 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Analysis of nonsense mutations in CRC, OVC and a number of other cancers indicates the need to expand the predictable risk factors for cancer to include, in addition to random polymerase errors, the methylation status of gene body CGA codons in tumor suppressor genes.
|
28137366 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical staining of tumor sections revealed overexpression of the LH/hCG receptor.
|
21324830 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Among the 12 patients with parathyroid cancer, 1 had a germ-line mutation of the HRPT2 at exon 7, codon 234, CGA (Arg) to TGA (Stop), and 1 patient had a tumor-specific mutation at exon 1, nucleotide 34-37 delAACA.
|
20480190 |
2010 |
|
PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the 12 patients with parathyroid cancer, 1 had a germ-line mutation of the HRPT2 at exon 7, codon 234, CGA (Arg) to TGA (Stop), and 1 patient had a tumor-specific mutation at exon 1, nucleotide 34-37 delAACA.
|
20480190 |
2010 |